Virtus Investment Advisers’s Vaxcyte PCVX Stock Holding History

Virtus Investment Advisers’s Portfolio PCVX Stock Details PCVX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$401K	Buy	6,894 +768	+13%	+$41.7K	0.09%	277
2026 Q1	$356K	Buy	6,126 +147	+2%	+$7.98K	0.1%	258
2025 Q4	$276K	Buy	5,979 +2,677	+81%	+$120K	0.08%	278
2025 Q3	$119K	Buy	3,302 +573	+21%	+$19K	0.03%	406
2025 Q2	$88.7K	Buy	2,729 +857	+46%	+$28.1K	0.03%	387
2025 Q1	$70.7K	Buy	+1,872	New	+$150K	0.02%	453
2024 Q2	–	Sell	-3,178	Closed	-$217K	–	367
2024 Q1	$217K	Hold	3,178	–	–	0.16%	183
2023 Q4	$200K	Hold	3,178	–	–	0.15%	191
2023 Q3	$162K	Hold	3,178	–	–	0.11%	193
2023 Q2	$159K	Hold	3,178	–	–	0.11%	208
2023 Q1	$119K	Sell	3,178 -109	-3%	-$4.62K	0.08%	237
2022 Q4	$158K	Buy	+3,287	New	+$129K	0.11%	220

Other funds holding PCVX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Jupiter Topco New York $245B AUM

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Virtus Investment Advisers's PCVX Position: Q2 2026 in Review

Virtus Investment Advisers increased its Vaxcyte (PCVX) stake by 13% in Q2 2026, buying an estimated $41.7K and bringing the position to 6,894 shares worth $401K. The position accounts for 0.09% of the portfolio, ranked #277.

Virtus Investment Advisers first reported a position in PCVX in Q4 2022 and has held it in 12 quarters since. 331 funds tracked by Wall St. Rank hold PCVX as of Q2 2026.

Virtus Investment Advisers held 6,894 shares of Vaxcyte worth $401K as of Q2 2026.
Virtus Investment Advisers bought 768 Vaxcyte shares in Q2 2026, an estimated $41.7K.
Vaxcyte made up 0.09% of Virtus Investment Advisers's portfolio in Q2 2026, its #277 holding.
Virtus Investment Advisers first reported a position in Vaxcyte in Q4 2022 and has held it in 12 quarters since.
331 funds tracked by Wall St. Rank held Vaxcyte as of Q2 2026.

Based on Virtus Investment Advisers's 13F filing for Q2 2026, filed 11 Aug 2026.